CERo Therapeutics (NASDAQ:CERO) Receives Buy Rating from D. Boral Capital

D. Boral Capital reaffirmed their buy rating on shares of CERo Therapeutics (NASDAQ:CERO) in a report issued on Monday morning,Benzinga reports. They currently have a $30.00 price objective on the stock.

Several other research firms also recently issued reports on CERO. D Boral Capital raised CERo Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Monday, June 23rd. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of CERo Therapeutics in a research note on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $45.00.

CERo Therapeutics Stock Up 0.6%

NASDAQ:CERO opened at $3.33 on Monday. CERo Therapeutics has a 52-week low of $3.15 and a 52-week high of $895.40. The stock has a fifty day simple moving average of $6.44 and a 200-day simple moving average of $9.66.

CERo Therapeutics (NASDAQ:CERO) last released its quarterly earnings results on Friday, August 22nd. The company reported ($61.71) earnings per share (EPS) for the quarter, topping the consensus estimate of ($70.23) by $8.52.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in CERo Therapeutics stock. Armistice Capital LLC acquired a new position in shares of CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) during the 1st quarter, according to its most recent filing with the SEC. The institutional investor acquired 312,000 shares of the company’s stock, valued at approximately $228,000. Armistice Capital LLC owned 5.80% of CERo Therapeutics at the end of the most recent reporting period. 29.64% of the stock is owned by institutional investors and hedge funds.

CERo Therapeutics Company Profile

CERo Therapeutics Holdings, Inc, an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.